NanoViricides, Inc. President Dr. Anil R. Diwan was recently interviewed on the Mission Matters Podcast by Adam Torres. During the discussion, Dr. Diwan outlined the company's mission to revolutionize antiviral treatment, likening their approach to how penicillin transformed bacterial infection therapy. He explained that NanoViricides’ technology differs from traditional antiviral methods, offering broad-spectrum drugs that viruses cannot evade, as the drugs mimic essential host-side features needed for viral infection. This approach does not rely on the patient’s immune system, making it suitable for a broad range of patients, including those who are immunocompromised. Dr. Diwan also highlighted the company’s lead drug candidate, NV-387, which has demonstrated strong efficacy in animal models against viruses such as Influenza, RSV, Coronaviruses, MPox, Smallpox, and Measles, outperforming existing influenza treatments. The full interview is available at https://youtu.be/nU_2dgd-u1g.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NanoViricides Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1132242) on February 02, 2026, and is solely responsible for the information contained therein.